GlassScriptPhysician profile
Ronald Irwin Jacobson
NPI 1164519120
$3,788.18
in general payments reported to CMS, 2019-2025
29 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,946 · 2020: $408 · 2021: $887 · 2022: $135 · 2023: $237 · 2024: $51.19 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,329.96 | 2019-2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $236.89 | 2019-2020 | |
| Eisai INC. | $217.73 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $183.60 | 2019-2021 | |
| Tris Pharma INC | $178.56 | 2019-2021 | |
| Eli Lilly and Company | $175.00 | 2021 | |
| Greenwich Biosciences, INC. | $169.92 | 2019-2021 | |
| Neuropace, INC. | $162.10 | 2023 | |
| Aquestive Therapeutics, INC. | $135.44 | 2019-2020 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $135.00 | 2022 | |
| Ucb, INC. | $123.90 | 2025 | |
| Novartis Pharmaceuticals Corporation | $89.83 | 2019-2020 | |
| Sk Life Science, INC. | $85.09 | 2021 | |
| Shire North American Group INC | $74.47 | 2019 | |
| Csl Behring | $70.08 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $58.60 | 2019-2020 | |
| Neos Therapeutics, LP | $47.99 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.41 | 2019-2020 | |
| Harmony Biosciences LLC | $35.57 | 2020 | |
| Mallinckrodt Enterprises LLC | $34.49 | 2019 | |
| Abbvie INC. | $34.34 | 2024 | |
| Corium, LLC | $33.11 | 2023 | Azstarys |
| Vertical Pharmaceuticals, LLC | $32.25 | 2019-2020 | |
| Adlon Therapeutics L.P. | $23.61 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.77 | 2020 | |
| Sarepta Therapeutics, INC. | $17.29 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $16.85 | 2024 | |
| Livanova USA, INC. | $12.33 | 2020 | |
| Travere Therapeutics, INC. | $8.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.